恩格列净、2型糖尿病患者的心血管结局及死亡率 - Suppr

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

作者信息

Rosenstein Robert, Hough Augustus

机构信息

West Palm Beach Veterans Affairs Medical Center, West Palm Beach, FL

出版信息

N Engl J Med. 2016 Mar 17;374(11):1093-4. doi: 10.1056/NEJMc1600827.

DOI:10.1056/NEJMc1600827

PMID:26981944

Abstract

摘要

相似文献

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

N Engl J Med. 2016 Mar 17;374(11):1093-4. doi: 10.1056/NEJMc1600827.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

N Engl J Med. 2016 Mar 17;374(11):1092-3. doi: 10.1056/NEJMc1600827.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

N Engl J Med. 2016 Mar 17;374(11):1092. doi: 10.1056/NEJMc1600827.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

N Engl J Med. 2016 Mar 17;374(11):1094. doi: 10.1056/NEJMc1600827.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

N Engl J Med. 2016 Mar 17;374(11):1093. doi: 10.1056/NEJMc1600827.

Preventing cardiovascular events with empagliflozin: at what cost?

Lancet Diabetes Endocrinol. 2015 Dec;3(12):931. doi: 10.1016/S2213-8587(15)00439-8.

ACP Journal Club. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years.

Ann Intern Med. 2016 Jan 19;164(2):JC2. doi: 10.7326/ACPJC-2016-164-2-002.

In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.

Am Fam Physician. 2016 Mar 1;93(5):410.

[Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].

Praxis (Bern 1994). 2016 Mar 16;105(6):349-50. doi: 10.1024/1661-8157/a002288.

The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.

Diabetologia. 2017 Mar;60(3):395-398. doi: 10.1007/s00125-016-4194-y. Epub 2017 Jan 11.

引用本文的文献

Empagliflozin Attenuates Pulmonary Arterial Remodeling Through Peroxisome Proliferator-Activated Receptor Gamma Activation.

ACS Pharmacol Transl Sci. 2024 Aug 1;7(9):2725-2738. doi: 10.1021/acsptsci.4c00127. eCollection 2024 Sep 13.

Sodium-glucose cotransporter-2 inhibitors improve cardiovascular outcomes post-acute coronary syndrome complicated by acute heart failure.

Front Cardiovasc Med. 2024 May 20;11:1383669. doi: 10.3389/fcvm.2024.1383669. eCollection 2024.

Cardiac lipotoxicity and fibrosis underlie impaired contractility in a mouse model of metabolic dysfunction-associated steatotic liver disease.

FASEB Bioadv. 2024 Mar 28;6(5):131-142. doi: 10.1096/fba.2023-00139. eCollection 2024 May.

The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes.

Cureus. 2023 Jan 7;15(1):e33484. doi: 10.7759/cureus.33484. eCollection 2023 Jan.

Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China.

Front Cardiovasc Med. 2022 Nov 16;9:1022020. doi: 10.3389/fcvm.2022.1022020. eCollection 2022.

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary.

Front Cardiovasc Med. 2022 Sep 21;9:1010693. doi: 10.3389/fcvm.2022.1010693. eCollection 2022.

Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts.

Front Aging. 2021;2. doi: 10.3389/fragi.2021.681513. Epub 2021 Jun 8.

Dapagliflozin Ameliorates STZ-Induced Cardiac Hypertrophy in Type 2 Diabetic Rats by Inhibiting the Calpain-1 Expression and Nuclear Transfer of NF-B.

Comput Math Methods Med. 2022 Jan 20;2022:3293054. doi: 10.1155/2022/3293054. eCollection 2022.

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians.

Metabolites. 2021 Nov 21;11(11):794. doi: 10.3390/metabo11110794.

Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial.

Diabetes Care. 2021 Jun;44(6):1324-1333. doi: 10.2337/dc20-2109. Epub 2021 Apr 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献